StockNews.AI
ALT
StockNews.AI
4 days

Berger Montague PC Investigates Securities Claims Against Altimmune, Inc. (NASDAQ: ALT)

1. Investigation into securities fraud for Altimmune is underway. 2. Class action lawsuit concerns purchases from August 10, 2023, to June 25, 2025. 3. Altimmune’s IMPACT study failed, causing a 53% stock price drop. 4. Management downplayed trial results, suggesting future improvements. 5. Investors have until October 6, 2025, to join the lawsuit.

5m saved
Insight
Article

FAQ

Why Very Bearish?

The significant stock drop shows investor confidence has been severely shaken, reminiscent of past instances where clinical trial failures led to major price declines in biotech stocks.

How important is it?

The investigation and lawsuit amplify concerns around Altimmune’s transparency and credibility, affecting investor sentiment and potential recovery.

Why Short Term?

The impact is immediate due to legal implications and market reactions to trial results, but recovery may take longer depending on future trial outcomes.

Related Companies

ACADGNFTMRNA
, /PRNewswire/ -- Berger Montague PC is investigating potential securities fraud claims on behalf of investors of Altimmune, Inc. (NASDAQ: ALT) ("Altimmune" or the "Company") following the filing of a securities class action lawsuit filed on behalf of investors who purchased or otherwise acquired Altimmune securities between August 10, 2023 through June 25, 2025 (the "Class Period"). Investor Deadline: Investors who purchased or acquired Altimmune securities during the Class Period may, no later than October 6, 2025, seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE. Altimmune, headquartered in Gaithersburg, Maryland, is a clinical-stage biopharmaceutical company. The lawsuit alleges that on June 26, 2025, Altimmune announced that its IMPACT study had failed to achieve statistical significance in the trial's primary endpoint of fibrosis reduction, citing a higher-than-expected placebo response. Despite management's prior optimistic statements, the Company downplayed the poor results, attributing the outcome to the Phase 2 nature of the trial and suggesting improvements in a future Phase 3 study. Following this disclosure, Altimmune's stock plunged 53%, from a close of $7.71 per share on June 25, 2025, to a close of $3.61 on June 26, 2025, causing heavy losses for investors. If you are an Altimmune investor and would like to learn more about this action, CLICK HERE or please contact Berger Montague: Andrew Abramowitz at [email protected] or (215) 875-3015, or Caitlin Adorni at [email protected] or (267)764-4865. About Berger MontagueBerger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco, Chicago, Malvern, PA, and Toronto has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States. For more information or to discuss your rights, please contact:Andrew Abramowitz, Senior CounselBerger Montague(215) 875-3015[email protected] Caitlin AdorniBerger Montague(267) 764-4865[email protected] SOURCE Berger Montague WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News